uniQure (QURE) announced this morning that collaboration partner Bristol-Myers (BMY) increased its equity stake in the company to 9.9% and also made a payment of $15M for selection of three targets for total payments of $53M. uniQure is now eligible for milestone payments of $254M for the lead S100A1 candidate and up to $217M for each additional candidate as well as royalties on net sales in the single- to double-digit range, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. He views the terms as attractive for uniQure and reiterates an Overweight rating on the stock with a $40 price target.